Published in:
Open Access 01-12-2020 | Albuminuria | Correction
Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Published in: Diabetes Therapy | Issue 12/2020
Login to get accessExcerpt
In the original article, Table 1 was published with a type-set error. The correct Table 1 is given below.
Table 1
Demographics and baseline characteristics for participants with Type 2 diabetes, by baseline CKD category—8-study pool (intention-to-treat analysis set)
|
Characteristic
|
CKD3
|
CKD2
|
||
|---|---|---|---|---|
|
EQW
N = 182
|
All comparators
N = 207
|
EQW
N = 772
|
All comparators
N = 1043
|
|
|
Men, n (%)
|
105 (57.7)
|
105 (50.7)
|
419 (54.3)
|
608 (58.3)
|
|
Age (years), mean (SD)
|
62.5 (9.0)
|
62.2 (9.0)
|
56.9 (9.3)
|
56.9 (9.5)
|
|
Age < 65 years, n(%)
|
102 (56.0)
|
120 (58.0)
|
613 (79.4)
|
820 (78.6)
|
|
Race, White, n (%)
|
66 (36.3)
|
89 (43.0)
|
522 (67.6)
|
685 (65.7)
|
|
Race, Asian, n (%)
|
111 (61.0)
|
106 (51.2)
|
157 (20.3)
|
227 (21.8)
|
|
Race, Black or African American, n (%)
|
0
|
5 (2.4)
|
38 (4.9)
|
39 (3.7)
|
|
Body weight (kg), mean (SD)
|
76.9 (19.3)
|
78.5 (17.7)
|
88.8 (19.3)a
|
87.8 (19.1)
|
|
BMI (kg/m2), mean (SD)
|
28.3 (5.1)
|
29.6 (5.8)
|
31.6 (5.5)a
|
31.4 (5.6)
|
|
BMI ≥ 35 (kg/m2), n (%)
|
24 (13.2)
|
40 (19.3)
|
196 (25.4)
|
246 (23.6)
|
|
Sitting SBP (mm Hg), mean (SD)
|
133 (14.3)
|
136 (17.2)
|
131 (13.8)
|
131 (14.6)
|
|
Sitting DBP (mm Hg), mean (SD)
|
77 (9.7)
|
79 (9.6)
|
79 (9.3)
|
79 (8.8)
|
|
eGFR (mL/min/1.73 m2), mean (SD)
|
52.7 (5.6)
|
53.3 (5.1)
|
75.9 (8.4)
|
75.9 (8.6)
|
|
uACR (mg/g), mean (SD), median
|
105 (348), 14.2
(n = 151)
|
116 (438), 20.4
(n = 165)
|
54.1 (171), 10.6
(n = 528)
|
47.9 (158), 10.6
(n = 810)
|
|
< 30 mg/g (normal), n (%)
|
96 (52.7)
|
108 (52.2)
|
398 (51.6)
|
609 (58.4)
|
|
≥ 30 to ≤ 300 mg/g (moderately increased albuminuria), n (%)
|
45 (24.7)
|
46 (22.2)
|
108 (14.0)
|
178 (17.1)
|
|
> 300 mg/g (severely increased albuminuria), n (%)
|
10 (5.5)
|
11 (5.3)
|
22 (2.8)
|
23 (2.2)
|
|
Unknownb, n (%)
|
31 (17.0)
|
42 (20.3)
|
244 (31.6)
|
233 (22.3)
|
|
Duration of T2D (years), mean (SD)
|
9.7 (6.8)
|
9.5 (6.8)
|
7.6 (6.3)a
|
6.3 (5.5)a
|
|
HbA1c (%), mean (SD)
|
8.3 (0.8)
|
8.5 (0.9)
|
8.5 (1.1)
|
8.4 (1.1)
|
|
FPG (mg/dL), mean (SD)
|
168 (46.7)
(n = 181)
|
176 (50.2)
(n = 203)
|
172 (50.0)
(n = 751)
|
171 (46.8)
(n = 1026)
|
|
Baseline anti-hyperglycaemic drugsc
|
||||
|
None, n (%)
|
8 (4.4)
|
34 (16.4)
|
135 (17.5)
|
299 (28.7)
|
|
Metformin, n (%)
|
155 (85.2)
|
159 (72.5)
|
529 (68.5)
|
647 (62.0)
|
|
Sulfonylureas, n (%)
|
4 (2.2)
|
10 (4.8)
|
55 (7.1)
|
55 (5.3)
|
|
Thiazolidinediones, n (%)
|
36 (19.8)
|
31 (15.0)
|
32 (4.1)
|
39 (3.7)
|
|
Insulin, n (%)
|
18 (9.9)
|
22 (10.6)
|
107 (13.9)
|
98 (9.4)
|